Tieton Capital Management LLC Reduces Stock Holdings in ChromaDex Co. (NASDAQ:CDXC)

Tieton Capital Management LLC cut its position in shares of ChromaDex Co. (NASDAQ:CDXC) by 0.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,956,120 shares of the company’s stock after selling 11,940 shares during the quarter. ChromaDex makes up about 5.6% of Tieton Capital Management LLC’s holdings, making the stock its 4th biggest position. Tieton Capital Management LLC owned approximately 3.87% of ChromaDex worth $10,790,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in ChromaDex in the first quarter worth $54,000. Acadian Asset Management LLC bought a new stake in shares of ChromaDex during the first quarter valued at about $67,000. Lazard Asset Management LLC purchased a new stake in shares of ChromaDex in the first quarter worth about $43,000. Perritt Capital Management Inc. purchased a new position in ChromaDex during the first quarter valued at approximately $139,000. Finally, Miracle Mile Advisors LLC bought a new stake in ChromaDex during the 2nd quarter worth approximately $27,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on CDXC. HC Wainwright raised their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 4th. StockNews.com lowered ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 18th. Finally, Roth Mkm lifted their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

ChromaDex Price Performance

Shares of NASDAQ:CDXC opened at $7.44 on Friday. The company has a market cap of $568.27 million, a PE ratio of 744.74 and a beta of 1.88. The stock’s 50-day moving average is $4.53 and its 200 day moving average is $3.56. ChromaDex Co. has a 1 year low of $1.32 and a 1 year high of $7.85.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The business had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period last year, the business posted ($0.01) earnings per share. Analysts expect that ChromaDex Co. will post 0.04 EPS for the current fiscal year.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.